Skip to main content Skip to section navigation Skip to footer

Inhibikase Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • IkT-148009 for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Jan 27, 2023 4:05pm EST

Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules

Jan 25, 2023 1:00pm EST

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules

Jan 25, 2023 8:35am EST

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders

Jan 25, 2023 8:05am EST

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease

Dec 12, 2022 4:05pm EST

Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Dec 07, 2022 4:05pm EST

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs

Nov 22, 2022 8:00am EST

Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022 5:45pm EST

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

Nov 08, 2022 8:00am EST

Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Nov 07, 2022 8:00am EST

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap